CL2025002930A1 - Programa de dosificación de un inhibidor de her.2 - Google Patents

Programa de dosificación de un inhibidor de her.2

Info

Publication number
CL2025002930A1
CL2025002930A1 CL2025002930A CL2025002930A CL2025002930A1 CL 2025002930 A1 CL2025002930 A1 CL 2025002930A1 CL 2025002930 A CL2025002930 A CL 2025002930A CL 2025002930 A CL2025002930 A CL 2025002930A CL 2025002930 A1 CL2025002930 A1 CL 2025002930A1
Authority
CL
Chile
Prior art keywords
her2 inhibitor
dosing schedule
inhibitor dosing
her2
cancer
Prior art date
Application number
CL2025002930A
Other languages
English (en)
Inventor
Baum Anke
Scharn Dirk
Schroeter Lukas
Von Wangenheim Ute
Wind Sven
Serra Fibla Josep
Chylinski Krzysztof
Gibson Neil
Neumueller Ralph
Sadrolhefazi Behbood
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2025002930A1 publication Critical patent/CL2025002930A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un programa de dosificación de un inhibidor de HER2 útil en la prevención y/o tratamiento del cáncer, en particular a sus dosis y administración en segunda o posterior línea.
CL2025002930A 2023-03-29 2025-09-26 Programa de dosificación de un inhibidor de her.2 CL2025002930A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP23382299 2023-03-29
EP23383067 2023-10-19
EP23383302 2023-12-15
EP24382331 2024-03-27

Publications (1)

Publication Number Publication Date
CL2025002930A1 true CL2025002930A1 (es) 2026-01-16

Family

ID=90719285

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002930A CL2025002930A1 (es) 2023-03-29 2025-09-26 Programa de dosificación de un inhibidor de her.2

Country Status (8)

Country Link
EP (1) EP4687907A2 (es)
KR (1) KR20260004349A (es)
CN (1) CN121263188A (es)
AU (1) AU2024247020A1 (es)
CL (1) CL2025002930A1 (es)
IL (1) IL323596A (es)
MX (1) MX2025011417A (es)
WO (1) WO2024200637A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228858A1 (en) * 2023-12-20 2025-07-17 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Also Published As

Publication number Publication date
KR20260004349A (ko) 2026-01-08
WO2024200637A3 (en) 2024-12-05
AU2024247020A1 (en) 2025-10-30
CN121263188A (zh) 2026-01-02
WO2024200637A2 (en) 2024-10-03
EP4687907A2 (en) 2026-02-11
MX2025011417A (es) 2025-11-03
IL323596A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
MX2022005812A (es) Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX2025000105A (es) Inhibidor de kras g12c para el tratamiento del cancer
EA202092154A1 (ru) Комбинированная терапия
CL2025002930A1 (es) Programa de dosificación de un inhibidor de her.2
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
BR112022010086A2 (pt) Dosagem do inibidor de shp2 e métodos de tratamento de câncer
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
CL2023003357A1 (es) Régimen de dosis para terapia combinada dirigida a dll3 y pd-1
MA69153A1 (fr) Méthodes de traitement d'une splénomégalie
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
BR112021002145A2 (pt) Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2024004899A (es) Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
BR112017024073A2 (pt) métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2025007170A (es) Esquema de dosificacion de una dispersion solida de un inhibidor de her2
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
AR125296A1 (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها